Scitech Pharma

SciTech Development is a clinical-stage oncology company focused on developing innovative drug delivery solutions for proven but difficult-to-deliver compounds. The company's lead candidate, ST-001 (nano-fenretinide), utilizes their proprietary SciTech Delivery Platform (SDP) to overcome the bioavailability and toxicity issues historically associated with fenretinide. SciTech is currently advancing ST-001 through clinical trials for various orphan oncology indications, including T-cell lymphomas. Their approach combines a well-characterized therapeutic agent with a novel nanoparticle delivery system to improve patient outcomes in underserved cancer populations. The company aims to expand its pipeline by applying the SDP technology to other high-potential oncology drugs.